Trends and Disparities in Mortality due to Pulmonary Embolism Among Adults With Atrial Fibrillation From 1999 to 2020: Insights From the CDC WONDER Database Authors: Eeman Ahmad, Mishal Khan, Muhammad Ans, Hoor Ul Ain, Ahmad Qaisar, Shahzaib Ahmed, Olivier Uwishema, Ibrahim Nagmeldin Hassan, Muhammad Saad, Abbas Hayat Mallick, M Chadi Alraies Published: 2026 ABSTRACT ABSTRACTBackgroundPulmonary embolism (PE) remains a major cause of cardiovascular mortality, and atrial fibrillation (AF) significantly worsens its outcomes. However, long‐term trends and disparities in PE mortality among patients with AF remain poorly characterized.MethodsUsing the CDC WONDER database (1999–2020), we identified adults with PE as the underlying cause of death and AF as a contributing cause using ICD‐10 codes I26 and I48. Age‐adjusted mortality rates (AAMRs) and annual percentage changes (APCs) were calculated via Joinpoint regression. Subgroup analyses were done based on the pre‐, during, and post‐COVID‐19 pandemic era.ResultsA total of 5499 deaths were recorded with PE and coexisting AF. Overall mortality remained stable from 1999 to 2009 (APC: –0.27; 95% CI: −2.12 to 1.60), then rose sharply from 2009 to 2020 (APC: 3.68; 95% CI: 2.29–5.10). Males had higher mortality (AAMR: 0.077) than females (0.065), with faster increases over time. Non‐metropolitan areas showed greater mortality (AAMR: 0.082) than metropolitan areas (0.063), with steeper APCs (2.73% vs. 2.00%). Regionally, the Midwest (AAMR: 0.077) and South (0.073) bore the highest burden. States with the highest mortality included Vermont and Maryland. Most deaths occurred in inpatient settings (55.7%), followed by nursing homes (15.8%) and decedents' homes (14.5%). Notably, states with the lowest AAMRs were New York, Louisiana, and Florida.ConclusionsMortality due to PE with AF as a contributor has increased significantly since 2009, with marked sex, regional, and urban–rural disparities. These findings underscore the growing public health burden and the need for targeted regional responses. Introduction Pulmonary embolism (PE) is the third leading cause of cardiovascular‐related mortality in the US, making it a critical public health concern [1]. An alarming trend of increasing PE‐associated mortality, especially among individuals younger than 70, has been found [2]. The mortality risk in PE patients can be attributed to various factors, with age, chronic obstructive pulmonary disease (COPD), heart failure, and atrial fibrillation recognized as significant contributors [3]. Recent studies reveal a significant association of atrial fibrillation (AF) with PE, with mechanisms involving blood stasis in the atrial appendage and subsequent thrombus formation believed to be the main cause [4]. One meta‐analysis found a significant link between the two, with an incidence ratio of 4.18, indicating that AF patients have a markedly increasing risk of developing PE [4]. Moreover, age, obesity, heart failure, and inflammatory states have been identified as common risk factors for the two conditions, increasing their rates of coexistence [5]. PE patients with pre‐existing AF experience worse clinical outcomes, including cardiac tamponade, acute kidney injury, and higher mortality odds than patients without [6]. In addition, right ventricular dysfunction (RVD) is one of the critical determinants of worsening PE prognosis that requires prompt identification and targeted management [7]. PE patients with coexisting AF experience increased rates of RVD, which worsens outcomes. One study found a 56% rate of RVD in AF patients compared to a 39% rate in those without AF, resulting in a four‐fold increase in patient mortality risk (OR 4.9) [8]. AF patients also present with more severe forms of PE than patients without, leading to poor clinical outcomes [9]. Despite the well‐documented association of AF and PE, studies have primarily focused on the underlying mechanisms, prognostic factors, and treatment strategies involved. There is a lack of research on the mortality rates, patterns, and overall burden associated with these conditions. This study aims to address these gaps by analyzing trends in PE and AF‐related mortality and determining disparities among different demographic groups. Methods Study Design This descriptive epidemiological study utilized data from the Centers for Disease Control and Prevention's Wide‐Ranging Online Data for Epidemiologic Research (CDC WONDER) platform [10]. We retrieved mortality records using ICD‐10 codes I26 (pulmonary embolism) and I48 (atrial fibrillation) [11], both of which have been validated in prior mortality trend analyses involving PE and AF [12, 13]. Individuals were included if PE was identified as the underlying cause of death and AF was listed as a contributing cause on death certificates from 1999 to 2020 in the United States. These data were extracted from the underlying and multiple cause‐of‐death files. As CDC WONDER provides publicly accessible, de‐identified data, institutional review board approval was not required. This study adhered to the Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) recommendations [14]. Data Abstraction We extracted PE‐related mortality data among adults with concurrent AF spanning 1999 to 2020. Variables were stratified by calendar year, sex, census region, urban–rural residence, state, and place of death. Census regions followed the U.S. Census Bureau's classification into Northeast, Midwest, South, and West [15]. Based on the 2013 NCHS classification, urban areas were those with ≥ 50 000 people, while rural areas had fewer than 50 000 [16]. Deaths were categorized by location: medical facilities, homes, nursing/long‐term care, hospice, or other. Crude and age‐adjusted mortality rates (AAMRs) with 95% confidence intervals (CIs) were collected using the 2020 U.S. standard population. Statistical Analysis Temporal trends in AAMRs were assessed using joinpoint regression, which detects significant shifts in trends by connecting linear segments on a logarithmic scale and identifying change points (“joinpoints”) [17]. Analyses were conducted using the Joinpoint Regression Program (Version 5.2.0) [18], employing the Monte Carlo Permutation method to determine the number of statistically significant joinpoints [19]. Annual percentage change (APC) and corresponding 95% CIs were calculated for each segment. The average annual percentage change (AAPC) was computed to summarize trends over the entire period. Two‐tailed p‐values < 0.05 were considered statistically significant. Subgroup Analysis For the subgroup analysis, to assess the impact of the pandemic‐era on mortality, we used the Provisional Multiple Cause of Death database from CDC WONDER, which provides mortality data for all U.S. residents from 2018 to 2023 based on death certificates. Deaths due to Pulmonary Embolism among adults with Atrial Fibrillation were assessed independently of COVID‐19, across pre‐, during, and post‐pandemic periods. To assess trends in mortality due to Pulmonary Embolism among adults with Atrial Fibrillation, we calculated the percentage change in age‐adjusted mortality rates across three periods: 2018–2019 (pre‐COVID), 2020–2021 (during COVID), and 2022–2023 (post‐COVID). Results Between 1999 and 2020, a total of 5499 deaths were recorded in the United States with pulmonary embolism as the underlying cause and atrial fibrillation listed as a contributing factor (Table 1). From 1999 to 2009, the AAMR remained relatively stable (APC: –0.27; 95% CI: −2.12 to 1.60), followed by a sharp increase thereafter (APC: 3.68; 95% CI: 2.29 to 5.10) (Figure 1 and Table 2). The burden of mortality was highest in medical inpatient facilities, accounting for 55.7% of deaths. This was followed by nursing homes or long‐term care facilities (15.8%), the decedent's home (14.5%), and outpatient settings (7.9%). The lowest burden was observed in hospice facilities (3.6%) and other locations (2.4%) (Table 1). TABLE 1Demographic characteristics of deaths due to pulmonary embolism among adults with atrial fibrillation in the United States from 1999 to 2020.VariableDeathsPopulation (billions) a Age‐adjusted mortality rate (95% CI)Overall54996.750.071 (0.069–0.073) Sex Female32763.430.065 (0.062–0.067)Male22233.320.077 (0.073–0.08) Census region Northeast9751.210.057 (0.053–0.061)Midwest13671.470.077 (0.073–0.081)South20492.500.073 (0.069–0.076)West11081.570.068 (0.064–0.072) Urbanization Metropolitan43025.740.063 (0.061–0.065)Non‐metropolitan11971.010.082 (0.077–0.087) Place of death Medical facility—inpatient3043 (55.7%)Medical facility—outpatient or ER434 (7.9%)Decedent's home792 (14.5%)Hospice facility199 (3.6%)Nursing home/long‐term care864 (15.8%)Other130 (2.4%)Abbreviation: CI, confidence interval. a Population values are expressed in billions and rounded to two decimal places. Demographic characteristics of deaths due to pulmonary embolism among adults with atrial fibrillation in the United States from 1999 to 2020. Abbreviation: CI, confidence interval. Population values are expressed in billions and rounded to two decimal places. Mortality due to pulmonary embolism among adults with atrial fibrillation stratified by gender in the United States from 1999 to 2020. TABLE 2Annual percentage changes (APCs) and average annual percentage changes (AAPCs) in mortality due to pulmonary embolism among adults with atrial fibrillation in the United States population from 1999 to 2020.VariableTrend segmentLower endpointUpper endpointAPC (95% CI)AAPC (95% CI) p Entire cohort119992009−0.27 (−2.11 to 1.60)1.78* (0.71–2.86)0.0010322200920203.68* (2.29 to 5.10) Sex Female1199920201.42* (0.74 to 2.11)1.42* (0.74–2.11)0.000295Male1199920202.28* (1.32 to 3.25)2.28* (1.32–3.25)0.000072 Census region Northeast1199920046.97 (−0.69 to 15.23)1.02 (−4.10 to 6.42)0.701506220042007−15.32 (−41.61 to 22.82)3200720202.93* (1.23 to 4.65)Midwest119992008−1.29 (−4.02 to 1.53)1.85* (0.44–3.28)0.0098622200820204.27* (2.65 to 5.90)South1199920201.78*(1.06 to 2.50)1.78* (1.06–2.50)0.000043West1199920202.42* (1.39 to 3.46)2.42* (1.39–3.46)0.000083 Urbanization Urban1199920202.00* (1.22 to 2.78)2.00* (1.22–2.78)0.000027Rural1199920202.73* (1.77 to 3.69)2.73* (1.77–3.69)0.000007Abbreviations: AAPC, average annual percent change; APC, annual percent change; CI, confidence interval.*Indicates that the APC or AAPC is significantly different from zero at the alpha = 0.05 level. Annual percentage changes (APCs) and average annual percentage changes (AAPCs) in mortality due to pulmonary embolism among adults with atrial fibrillation in the United States population from 1999 to 2020. Abbreviations: AAPC, average annual percent change; APC, annual percent change; CI, confidence interval. Indicates that the APC or AAPC is significantly different from zero at the alpha = 0.05 level. Sex Stratified Trends Across the study period, males exhibited the highest overall AAMR (0.077) compared to females (0.065) (Table 1). Among males, the mortality rate showed a marked increase from 1999 to 2020 (APC: 2.27; 95% CI: 1.32–3.25). In contrast, females experienced a more gradual rise in mortality (APC: 1.42; 95% CI: 0.74–2.11) (Figure 1, Table 2, and Table S1). Urbanization Stratified Trend Non‐metropolitan areas recorded a higher overall AAMR (0.082) than metropolitan areas (0.063) (Table 1). From 1999 to 2020, non‐metropolitan areas experienced a significant increase in mortality (APC: 2.73; 95% CI: 1.77–3.69), while metropolitan areas demonstrated a steady rise (APC: 2.00; 95% CI: 1.22–2.78) (Figure 2, Table 2, and, Table S2). Mortality due to Pulmonary Embolism among adults with Atrial Fibrillation stratified by 2013 urbanization in the United States from 1999 to 2020. Census Region Stratified Trends Among the four census regions, the Midwest had the highest overall AAMR (0.077), followed by the South (0.073), the West (0.068), and the Northeast (0.057) (Table 1). In the Midwest, AAMR declined between 1999 and 2008 (APC: –1.29; 95% CI: −4.02 to 1.53), then rose sharply through 2020 (APC: 4.27; 95% CI: 2.65–5.90). The Northeast showed an initial increase from 1999 to 2004 (APC: 6.97; 95% CI: −0.69 to 15.23), followed by a substantial decline through 2007 (APC: –15.32; 95% CI: −41.61 to 22.82), then an upward trend until 2020 (APC: 2.93; 95% CI: 1.23–4.65). Both the South (APC: 1.76; 95% CI: 1.06–2.50) and the West (APC: 2.42; 95% CI: 1.39–3.46) exhibited steady increases from 1999 to 2020 (Figure 3, Table 2, Table S3, and Figure S1). Mortality due to Pulmonary Embolism among adults with Atrial Fibrillation stratified by census region in the United States from 1999 to 2020. State Stratified Trends States with the highest overall AAMRs included Vermont (0.166), Maryland (0.145), and West Virginia (0.129). Conversely, the lowest AAMRs were observed in New York (0.045), Louisiana (0.043), and Florida (0.037) (Figure 4, Table S4, and Figure S2). Deaths‐related data for seven of the states in the U.S. was suppressed by the CDC WONDER, due to the presence of less than 10 deaths to protect confidentiality, and we did not attempt to recover, fill in or estimate suppressed values. State‐wise Mortality due to Pulmonary Embolism among adults with Atrial Fibrillation in the United States from 1999 to 2020. Impact of COVID‐19 on Mortality Rates (2018–2023) The overall AAMR was 0.087 (95% CI: 0.081–0.094) in the pre‐COVID period, 0.095 (95% CI: 0.088–0.102) during COVID, and 0.114 (95% CI: 0.107–0.122) in the post‐COVID era. Mortality rose by 9.2% from pre‐COVID to during COVID, followed by a 20.0% rise from during to post‐COVID. When compared with the pre‐COVID period, the post‐COVID AAMR remained 31.0% higher. Among males, a 30.9% increase was observed from pre‐COVID to COVID, followed by a 13.2% rise from COVID to post‐COVID. Compared with pre‐COVID, the post‐COVID rate remained higher by 48.1%. For females, mortality increased by 26.4% between pre‐COVID and COVID, then rose by 14.3% from COVID to post‐COVID, with the post‐COVID rate remaining 44.4% higher than pre‐COVID. Geographically, the Northeast demonstrated the greatest rise from pre‐COVID to post‐COVID era (69.6%), followed by the West (36.6%), the Midwest (28%), and the South (27.6%). Notably, in terms of place of death, the greatest rise from pre‐COVID to post‐COVID was reported at inpatient medical facilities (61.7%), while hospice facilities observed an overall drop (−14%) (Table 3). TABLE 3The impact of COVID‐19 on pulmonary embolism‐related mortality among patients with atrial fibrillation in the United States (2018–2023). Age adjusted mortality rate (AAMR) per 100 000 and percentage change across pre‐COVID, during COVID and post‐COVID periods.Pre‐COVID 2018–2019 (95% CI)During COVID 2020–2021 (95% CI)Post‐COVID 2022–2023 (95% CI)% change (from Pre‐COVID to During COVID)% change (from During COVID to Post‐COVID)% change (from Pre‐COVID to Post‐COVID) Overall 0.0870.0950.1149.220.031.0 Census region Northeast0.0560.0710.09526.833.869.6Midwest0.10.1120.12812.014.328.0South0.0870.1030.11118.47.827.6West0.0820.0870.1126.128.736.6 Sex Female0.0720.0910.10426.414.344.4Male0.0810.1060.1230.913.248.1 Place of death * Medical facility—inpatient32642652730.723.761.7Medical facility—outpatient58746627.6−10.813.8Decedent's home13318220036.89.950.4Hospice facility573749−35.132.4−14.0Nursing home/Long term care9893106−5.114.08.2Other222127−4.528.622.7*For place of death, only total number of deaths have been reported. The impact of COVID‐19 on pulmonary embolism‐related mortality among patients with atrial fibrillation in the United States (2018–2023). Age adjusted mortality rate (AAMR) per 100 000 and percentage change across pre‐COVID, during COVID and post‐COVID periods. For place of death, only total number of deaths have been reported. Discussion Our analysis of US mortality data from 1999 to 2023 demonstrated a concerning rise in pulmonary embolism (PE) related mortality with atrial fibrillation (Afib) as the contributing factor, particularly after 2009. Notably, men experienced both higher baseline mortality and more rapid increases than women, non‐metropolitan residents exhibited worse outcomes than those in metropolitan areas, and the Midwest and South demonstrated the highest regional burden and the steepest increase. We also found that in‐hospital mortality was the major place of death, followed by nursing homes, long‐term care facilities, decedents' homes and hospices. These findings expand previous clinical knowledge on Afib as a predictor of acute PE and highlight the public‐health burden of Afib‐PE related mortality in various geographic and demographic settings across the US. Our observation of stable mortality during the first decade and subsequent increase after 2009 mirrors the findings of previous national level analysis and global trends where both PE and AF have increased in incidence and mortality [20, 21, 22, 23]. These trends are probably driven by aging populations, increased survival from previous cardiovascular events, and greater detection via improved diagnostics and outpatient monitoring [24]. The advent of double anticoagulation therapy (DOAC) around this time, which reduces thromboembolic risk on its own, should have further reduced mortality; however, several epidemiological shifts occurring concurrently might explain the observed rise in mortality. The widespread adoption of high sensitivity Computed Tomographic Pulmonary Angiography (CTPA) has led to an “epidemic” of subsegmental diagnosis. While this increases documented incidence, it often identifies low risk cases that do not change mortality outcomes, potentially diluting the perceived benefit of newer anticoagulants in population level data [25]. Additionally, post 2009, there has been a significant rise in the number of patients surviving after complex heart failure and malignancies, conditions which are highly prothrombotic and where PE often serves as a terminal event despite anticoagulation [26, 27, 28, 29, 30, 31, 32]. Prior studies have documented reductions in PE mortality until the late 2000s, but the spike thereafter that we identified may reflect a shift in the epidemiological landscape post 2010. a s improved stroke prevention in AF but may have also exposed lingering treatment disparities [26, 27, 28, 29]. Literature shows that AF worsens outcomes in acute PE, with increased inpatient mortality rate with likewise increase in 3‐ and 6‐month mortality [24, 33]. The higher AAMR observed in men in our study aligns with prior research showing men experience more severe AF phenotypes and higher rates of unrecognized AF, which contributes to higher thromboembolic events and cardiovascular mortality [34, 35]. Potential biological mechanisms including greater health burden of atrial fibrosis and metabolic risk factors in men may explain this pattern [34, 35, 36, 37, 38]. However, these are all epidemiological associations rather than direct causal pathways. Future areas of clinical registry studies should focus on incorporating smoking, obesity, BMI, and PESI score which can also potentially explain these findings. Rural areas had a higher and steeper rise in mortality as compared to urban areas possibly stemming from limited access to advanced diagnostic tools, like CT pulmonary angiography as well as limited availability of trained specialists, delaying diagnosis and intervention [20, 21, 39, 40]. Rural communities tend to be composed of aging populations as compared to urban ones; hence, they have more comorbid conditions like obesity and hypertension, further contributing to PE risk associated with AF [40, 41, 42]. Regionally, Midwest and South exhibited the highest mortality rate and the steepest upward trend from PE associated with AF, a pattern that parallels geographic disparities seen in cardiovascular disease burden and risk factor clustering [43, 44]. These areas are burdened by obesity, diabetes, hypertension, and socioeconomic disparity, which can further increase susceptibility to both PE and AF [20, 21, 40, 45]. Although coding practices may contribute to observed mortality differences, the consistency and magnitude of trends suggest a genuine regional concern. These findings underscore the need for regional interventions: expanding mobile diagnostic units, establishing anticoagulation clinics, and increased availability to specialists for better risk assessment and management, to address escalating PE mortality associated with AF [46, 47, 48]. The transition across pre, during and after Covid eras reveals a significant rise in AF‐associated PE mortality, characterized by a 31% overall increase in AAMR, suggesting a complex interplay between viral coagulopathy and healthcare displacement. The unique hypercoagulable state of COVID‐19 characterized by profound endothelial dysfunction and immunothrombosis can explain the initial 9.2% increase in AAMR during the acute phase of the pandemic (2020–2021) [49]. The subsequent 20% surge in the post Covid era points toward more enduring systemic issues [50, 51]. This delayed spike reflects a post‐acute sequelae of SARS‐CoV‐2, demonstrated by large scale longitudinal studies that the risk for venous thromboembolism and pulmonary embolism remains significantly elevated for up to 12 months following initial infection [52]. Furthermore, the dramatic rise in inpatient medical facility deaths during the post‐Covide era indicates a shift toward higher acuity presentations. This suggests that the pandemic‐induced disruption in afib management and anticoagulation monitoring led to more severe and fatal PE events upon eventual hospitalization [53, 54]. Collectively, these trends suggest that while covid‐19 acted as a direct biological catalyst for PE, its enduring impact on mortality is equally driven by degradation of chronic cardiovascular care and long‐term prothrombotic nature of the virus [55]. Pathophysiologically, AF increases the risk of PE through blood stasis in the left atrium and endothelial dysfunction, which promotes a hypercoagulable condition that can precipitate an emboli [5, 56]. Diagnostically, AF can also occur as a result of right ventricular strain in large PE, making the relationship bidirectional [5]. Although randomized studies indicate a causal relationship between PE and AF, acute care registries often consistently find that AF presence, whether new onset or pre‐existing, increases mortality in PE [2, 5, 21, 24]. However, large‐scale epidemiological studies on PE with AF as a contributory cause have been lacking. This study fills that gap, establishing the link between PE and AF at a population level. Strengths and Limitations Our study's strengths include a large dataset over 24 years, representative of the US population, with a specific focus on PE‐AF mortality, a previously unexplored domain. Nonetheless, several limitations warrant consideration. Death certificate data may misclassify cause or contributors of death; AF may be underreported particularly in sudden community death. We lacked data on anticoagulation use, PE severity, comorbidities, socioeconomic status and race/ethnicity which are key determinants of treatment and outcome. The sequence in which AF and PE occur cannot be discerned; AF could precede PE or arise as a consequence, making it difficult to establish causality. Also, our reliance on underlying mortality patterns can not prove that interventions would alter these trends, although clinical evidence suggests anticoagulation and acute care reduce fatality [26, 27, 28, 29, 48, 56]. Moreover, due to relatively small counts in some strata, the confidence intervals for some segments end up becoming wider when analyzing the trends (e.g., the trends for the northeast). Hence we advise caution to the readers that these estimates should be interpreted with care and may reflect statistical instability rather than true underlying trends. Furthermore, the CDC WONDER database suppresses cells with fewer than 10 deaths to protect confidentiality, which may result in the exclusion of certain state‐year combinations, particularly in less populous regions or for rare outcomes. This creates the potential for bias in geographic comparisons, as a result caution is advised while interpreting the results. Future Directions Future research should focus on linked cohort studies that combine ECG, imaging, and pharmacy data to unravel the temporal association between AF and PE and determine the effect of anticoagulation commencement, adherence, and intensity on mortality risk. Implementation trials in rural areas could evaluate the efficacy of telehealth‐delivered DOAC management, mobile PE clinics, and EMS protocols. A qualitative study should assess patient and caregiver priorities for the place of death, balancing acute therapy with end‐of‐life quality. Finally, studies focusing on the male predominance in PE‐AF mortality—investigating biological, behavioral, and healthcare‐access factors—are required to inform sex‐specific preventative efforts. Conclusion We found that PE with AF as a contributory cause has evolved from a stable mortality cause to a public health concern after 2010, disproportionately affecting men, rural residents, and those in the Midwest and South. The shift toward home and hospice deaths suggests both changes in care preferences and acute health care access. Addressing these challenges requires a multi‐faceted response: enhancing AF screening and anticoagulation, improving regional healthcare infrastructure, and integrating acute and palliative care pathways to reverse these adverse mortality trends. Author Contributions Eeman Ahmad: conceptualization, methodology, writing – review and editing; Mishal Khan: conceptualization, writing – original draft; Muhammad Ans: formal analysis, writing – review and editing; Hoor Ul Ain: conceptualization, writing – original draft; Ahmad Qaisar: conceptualization, writing – original draft; Shahzaib Ahmed: conceptualization, writing – review and editing; Ibrahim Nagmeldin Hassan: supervision, writing – review and editing; Muhammad Saad: supervision, writing – review and editing; Abbas Hayat Mallick: supervision, writing – review and editing; M Chadi Alraies: supervision, writing – review and editing; Olivier Uwishema: supervision, writing – review and editing. Funding The authors have nothing to report. Conflicts of Interest The authors declare no conflicts of interest. Supporting information Table S1: Mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020), stratified by sex. Table S2: Mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020), stratified by 2013 urbanization. Table S3: Mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020), stratified by Census Region. Table S4: State‐wise mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020). Table S5: Pre‐ (2018–2019), during (2020–2021), post‐ COVID‐19 (2022–2023) age‐adjusted mortality rates. Figure S1: Map showing mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020), stratified by Census Region. Figure S2: Map showing statewide mortality due to pulmonary embolism among adults with atrial fibrillation in the United States (1999–2020).